RD-111

N/A

Report date: 2022/03/01 16:04:26

Base Information

Drug NameRD-111

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityTumor necrosis factor receptor superfamily member 8 inhibitors

TargetsTumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Iaso Biotherapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A